TxCell puts partial hold on manufacturing in agreement with French regulator

24 June 2015

French biotech company TxCell (Euronext Paris: TXCL) has temporarily put its pilot manufacturing facility activities at Besançon in France on partial hold, in agreement with the French regulator.

The actions aim particularly at eliminating the risk of microbial contamination of released drug products, though no contamination has been found in any product manufactured and released from the site.

TxCell has taken the decision in order to ensure future compliance with Good Manufacturing Practice (GMP) at the facility. The Besançon site obtained manufacturing authorization on September 23, 2013, and GMP certification on June 10, 2014. The pilot manufacturing unit in Besançon is temporary and TxCell intends to move all production to a new commercial GMP facility in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK